Registered title, quoted from ClinicalTrials.gov
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07739186, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
Inclusion criterion 8
ECOG performance status score of 0 or 1;
Inclusion criterion 7
Must have at least one measurable lesion as defined by RECIST v1.1;
Inclusion criterion 6
Presence of small cell lung cancer, neuroendocrine carcinoma, sarcomatoid carcinoma components, or squamous carcinoma components exceeding 10%;
Exclusion criterion 1
Diagnosis of active malignancy within 3 years before study randomization;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07739186, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- Age ≥ 18 years;
- Expected survival time ≥ 3 months;
- Patients with locally advanced non-squamous non-small cell lung cancer;
- Agree to provide tumor tissue samples obtained at or after diagnosis of locally advanced or metastatic cancer;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- ECOG performance status score of 0 or 1;
- Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%;
- Organ function levels must meet the required criteria;
- Urinary protein ≤ 2+ or < 1000 mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy test must rule out pregnancy; patients must be non-lactating and must use highly effective contraceptive measures throughout the treatment period and for 7 months after the last dose. For male participants whose partners are women of childbearing potential, adequate barrier contraceptive measures must be used throughout the treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Presence of small cell lung cancer, neuroendocrine carcinoma, sarcomatoid carcinoma components, or squamous carcinoma components exceeding 10%;
- Evidence suggesting the presence of EGFR-sensitive mutations, etc.;
- Patients who have received prior systemic therapy;
- Prior receipt of therapies targeting the mechanism of tumor immunity;
- Prior receipt of antibody-drug conjugates (ADCs) using topoisomerase I inhibitors as the toxin, etc.;
- Trial participants who have received prior systemic anti-angiogenic therapy;
- Receipt of radical radiotherapy, major surgery, or large-field radiotherapy within 4 weeks before study randomization;
- History of severe cardiac or cerebrovascular disease;
- Receiving long-term systemic corticosteroid therapy (e.g., >10 mg/day prednisone) prior to the first dose;
- Active autoimmune diseases and inflammatory diseases;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
- Prolonged QT interval, complete left bundle branch block, etc.;
- Diagnosis of active malignancy within 3 years before study randomization;
- Hypertension poorly controlled by two antihypertensive medications;
- Patients with poorly controlled blood glucose;
- History of ILD requiring steroid therapy, current ILD, or ≥ grade 2 radiation pneumonitis, etc.;
- Concurrent pulmonary diseases resulting in clinically severe impairment of respiratory function;
- Patients with active central nervous system metastases;
- Occurrence of severe infection within 4 weeks before study randomization;
- Presence of large serous cavity effusions, or symptomatic serous cavity effusions, etc.;
- Imaging findings suggesting tumor invasion or encasement of abdominal, thoracic, or other regions;
- Presence of serious non-healing wounds, ulcers, or fractures within 4 weeks before signing informed consent;
- Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing informed consent;
- Patients with a history of inflammatory bowel disease, extensive bowel resection, immune-mediated enteritis, intestinal obstruction, or chronic diarrhea, etc.;
- History of allergy to recombinant humanized antibodies or allergy to the investigational drug, etc.;
- History of autologous or allogeneic stem cell transplantation;
- Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection;
- History of severe neurological or psychiatric disorders;
- Receipt of other unapproved investigational drugs or treatments within 4 weeks before study randomization;
- Trial participants who plan to receive or have received live vaccines within 28 days before study randomization;
- Other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this clinical trial due to complications or other circumstances.
Quoted from ClinicalTrials.gov, NCT07739186, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07739186, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.